Nascimento et al. evaluated 307 men who underwent ADT for prostate cancer with various agents, including gonadotropin hormone-releasing hormone (GnRH) agonists and antagonists for a mean duration of 17 months, and demonstrated that 24 months after cessation of ADT treatment, 8% of men remained at castrate level; additionally, 76% of men returned to a total T level > 300 ng/dl and 51% returned to baseline testosterone level [2]. In their study, lower baseline T levels and ADT duration > 6 months were associated with a lower likelihood of recovery to normal T at 24 months [2]. Here, GNRH1 is linked to prostate carcinoma.